*In both groups-anxiety, arrhythmia, asthma, ascending aortic aneurysm, chronic kidney disease, depression, diabetes mellitus, dyslipidemia, gout, hypothyroidism, obesity, systemic arterial hypertension, rheumatoid arthritis, polyarthritis, portal hypertension, fibrosing interstitial pneumonia, schistosomiasis, thrombocytopenic purpura, and thrombophilia; in the CTEPH group only-mutation in the prothrombin gene, anti-phospholipid syndrome, heterozygous factor V Leiden mutation, and anti-thrombin deficiency. This evidence concerns the gene F2 and chronic thromboembolic pulmonary hypertension.